American College of Neuropsychopharmacology (ACNP) Annual Meeting

AXS-05 | Major Depressive Disorder

ACNP Poster: Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain

Dr. Roger McIntyre, MD, FRCPC describes the “Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain” ACNP 2023 poster

Online Figure for the “Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain” ACNP 2023 poster

AXS-05 | Major Depressive Disorder

ACNP Poster: Assessment of Withdrawal Symptoms After Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results From the GEMINI Trial

Dr. Rakesh Jain, MD describes the "Assessment of Withdrawal Symptoms After Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results From the GEMINI Trial" ACNP 2023 Poster

AXS-05 | Major Depressive Disorder

ACNP Poster: Impact of AXS-05 (dextromethorphan-bupropion) on Depressive Symptoms, Anxiety, and Quality of Life in Patients with One Prior Treatment Failure: Results from the EVOLVE Long-Term, Open-Label Study

Dr. Greg Mattingly, MD describes the “Impact of AXS-05 (dextromethorphan-bupropion) on Depressive Symptoms, Anxiety, and Quality of Life in Patients with One Prior Treatment Failure: Results from the EVOLVE Long-Term, Open-Label Study” ACNP 2023 Poster